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CancerThe nuclear retinoic acid (RA) receptors (RARα, β and γ) are transcriptional transregulators, which control
the expression of speciﬁc gene subsets subsequently to ligand binding and to strictly controlled
phosphorylation processes. Consequently RARs maintain homeostasis through the control of cell proliferation
and differentiation. Today, it is admitted that, analogous to the paradigm established by the hematopoietic
system, most adult tissues depict a differentiation hierarchy starting from rare stem cells. Here we highlight
that the integrity of RARs is absolutely required for homeostasis in adults. Indeed, strictly controlled levels of
RARs are necessary for the correct balance between self-renewal and differentiation of tissue stem cells. In
addition, loss, accumulation, mutations or aberrant modiﬁcations of a speciﬁc RAR lead to uncontrolled
proliferation and/or to differentiation block and thereby to cancer. This article is part of a Special Issue
entitled: Translating nuclear receptors from health to disease.slating nuclear receptors from
l rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Nuclear retinoic acid (RA) receptors (RARs) consist of three
subtypes, α (NR1B1), β (NR1B2) and γ (NR1B3), encoded by separate
genes. For each subtype, there are at least 2 isoforms, which are
generated by differential promoter usage and alternative splicing and
differ only in their N-terminal regions. RARs are activated by retinoids,
which cover natural vitamin Ametabolites exempliﬁed by retinoid acid
and synthetic active analogs [1].
RARs function as ligand-dependent transcriptional regulators,
heterodimerized with retinoid X receptors (RXRs), which also consist
of three types, α NR2B1, β (NR2B2) and γ (NR2B3) [2–4]. As such they
regulate the expression of subsets of target genes involved in cellular
differentiation, proliferation and apoptosis [5–8]. Consequently, RARs
play critical roles in a variety of biological processes, including
development, reproduction, immunity, organogenesis and homeostasis,
as assessed byvitaminA-deﬁciency (VAD), pharmacological andgenetic
studies conducted in the mouse [9–13].
As a general trend, the RARα subtype has ubiquitous or quite
widespread expression patterns. In contrast, the other RARs (RARβ and
RARγ) show complex tissue speciﬁc expression [11]. The generation of
germline mutations of the RAR and RXR coding genes in mice by
homologous recombination [12] provided powerful tools to study the
role of speciﬁc RAR/RXRheterodimers during embryonic patterning and
organogenesis. However the determination of their functions in a
deﬁned adult cell type/tissue or at a given time of the adult life by this
strategy was limited, due to in utero lethality or arrest of thedevelopment of a given organ at an early stage. To overcome these
limitations, strategies for spatio-temporally controlled somatic muta-
genesis in mice have been designed [14] and provided invaluable
models to elucidate some physiological functions of RARs and RXRs in
adults. Such a strategy has been already applied to skin and liver [15,16],
which have the ability to proliferate during the whole adult life. It has
been also applied to hematopoietic stem cells (HSCs) [17], which serve
as a paradigm for understanding non-only stem cell biology, but also
tissue homeostasis due to their ability to supply blood cells for the entire
life of individuals.
In addition to physiological roles, RARs are also involved in diseases
and cancers subsequently to mutations, fusions to other proteins,
altered expression levels or aberrant post-translational modiﬁcations,
resulting into altered functions and disruption of homeostasis.
Herewewill survey the state of our current knowledge in the role of
the different RAR subtypes in healthy adults, focusing on cells or tissues
with constant renewal capacity suchas tissue stemcells (hematopoietic,
mesenchymal and neural stem cells). We will also review the recent
insights concerning the deregulation of RAR activities in some diseases
or cancers.
2. RAR structure and canonical RAR-mediated regulation of
transcription
RARs have a well-deﬁned domain organization and structure
(Fig. 1A), consisting mainly of an unstructured and non-conserved N-
terminal domain (NTD) and two highly conserved and structured
domains, a central DNA-binding domain (DBD) linked to a C-terminal
ligand-binding domain (LBD) [1,2,18]. Brieﬂy, the DBD contains two
typical cysteine-rich zinc-binding motifs and two alpha helices, which
cross at right angles, folding into a globular conformation to form the
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contains not only the ligand-binding pocket, but also the main
dimerization domain and a hydrophobic cleft involved in coregulator
binding. The LBD shows a common fold comprising 12 conserved alpha
helices and a short beta turn, arranged in three layers to form an
antiparallel «alpha-helical sandwich» (Fig. 1A).
In thepast 20 years, it has been established that the basicmechanism
for transcriptional regulation by RARs relies on DNA binding to speciﬁc
sequence elements located in the promoters of target genes and on
ligand-induced conformational changes in the LBD that direct the
dissociation/association of several coregulator complexes [1,2,19]. RARs
heterodimerized with RXRs bind to speciﬁc DNA sequences named RA
response elements (RAREs), composed typically of two direct repeats of
a core hexameric motif, PuG [G/T] TCA [18,20]. The classical RARE is a
5 bp-spaced direct repeat (referred to as DR5). However, the hetero-
dimers also bind todirect repeats separated by1 bp(DR1)or 2 bp (DR2).
Recently the development of high throughput technologies such as
chromatin immunoprecipitation (ChIP) coupled with array hybridiza-
tion or ﬂow cell sequencing expanded the repertoire of potential high
afﬁnity response elements [5,21].
When bound to RAREs in the absence of ligand, RARs are associated
with largeprotein complexes endowedwith enzymatic activities,which
maintain chromatin in a condensed and repressed state [22]. Ligand
binding, which is facilitated by RAR associationwith cellular RA binding
protein (CRABPII) [23,24], induces conformational changes in the LBD
[1,25], the most striking one being the repositionment of helix 12. This
structural switch provokes corepressors release and initiates an ordered
and coordinated recruitment of a series of coregulator complexes with
different enzymatic activities including histone acetyl and methyl
transferases, and DNA-dependent ATPases [26,27]. At the end, these
events alter the chromatin structure surrounding the promoter of target
genes and pave the way for the recruitment of the transcription
machinery including RNA Polymerase II and the general transcription
factors.
3. New pictures of RAR signaling: RARs are phosphoproteins and
cross-talk with kinase cascades
Today it is becoming increasingly evident that, in addition to these
classical genomic effects, RARs also induce non-genomic responses such
as the rapid and transient activation of several kinase cascades. Indeed,
in response to RA, RARs activate p38MAPK [28–30] and a downstream
mitogen and stress-activated kinase, MSK1 [31]. These non-genomic
effects are mediated by a subpopulation of RARs anchored at the
cytoplasmic side of the cell membrane ([32,33] and our unpublished
observations), suggesting a new paradigm by which RARs would
integrate membrane/cytoplasm events that would orchestrate several
post-traductional modiﬁcations in order to ﬁne-tune transcription [34].
In line with this, it emerged that RARs are phosphorylated in
response to RA [1,31] at two serine residues located in unstructured
domains that provide the ﬂexibility needed for modiﬁcations by
enzymes such as kinases. One serine is located in a loop between
helices 9 and 10 (L9-10) within the LBD and belongs to an arginine-
lysine-richmotif that corresponds to a consensusphosphorylationmotif
for several kinases including MSK1 (Fig. 1A). In contrast, the second
serine residue is located in a proline-richmotif within the NTD (Fig. 1A)
and is phosphorylated by cdk7 [35,36], which forms with cyclin H and
MAT1 the CAK subcomplex of the general transcription factor TFIIH.
Most interestingly, the correct positioning of cdk7 and thereby the
efﬁciencyof theNTDphosphorylation rely on thedockingof cyclinHat a
speciﬁc site of the LBD located in loop L8-9 and theN-terminal part ofH9
(Fig. 1A) [37].
Bruck et al. [31] demonstrated that in the case of the RARα subtype,
the phosphorylation of these two residues results from a coordinated
phosphorylation cascade startingwith thephosphorylationof the serine
in L9-10 (Fig. 1B). Phosphorylation of this residue increases thedynamics/ﬂexibility of the nearby loop L8-9 (Samarut et al., manuscript
submitted), which corresponds to the docking site of cyclin H [37].
Consequently, the binding efﬁciency of cyclin H is increased, allowing
the right positioning of cdk7 and the phosphorylation of the serine
located in theNTD by this kinase [38]. Finally phosphorylation of this N-
terminal residue allows the recruitment of RARα to promoters [31].
Note that the RARγ subtype can be phosphorylated at the same residues
and that phosphorylation of the NTD signals the dissociation of
vinexinβ, an actin-binding protein, which represses RARγ activity [39].
4. RAR functions in hematopoiesis
One of the best example of RAR functions in adults and for the entire
life of individuals is hematopoiesis, which refers to the formation and
development of the blood cells [40–42]. In adults, the major hemato-
poietic organ is thebonemarrowwherehematopoietic stemcells (HSCs)
reside as rare cells in individual niches, and must continuously supply
blood cells to host circulation and tissues (homeostasis) [43]. Because
mature blood cells are predominantly short lived, multipotent HSCs are
required throughout life to replenish multipotent progenitors, commit-
ted precursors and mature blood cells (red blood cells, megakaryocytic,
lymphocytes and myeloid cells that include monocytes/macrophages,
neutrophils and eosinophils) through differentiation processes (Fig. 2).
These processes are orchestrated by numerous factors such as cytokines,
growth factors and several transcription factors including RARs.
Simultaneously, theHSC pool has to bemaintained via cell fate decisions
of self-renewal, apoptosis/senescence or differentiation. Thus hemato-
poiesis requires a balancebetween theself-renewal of thehematopoietic
stem cells and their differentiation into the different lineages.
Easy access to hematopoietic cells has enabled a vast number of
studies over the last several decades and increased the understanding
about the role of RARs in the self-renewal and the differentiation of
HSCs. The hematopoietic system expresses signiﬁcantly the RARα and
RARγ subtypes (RARβ being generally poorly expressed), and thusmost
studies concentrated on these two nuclear receptors and compared the
behavior of bone marrow HSCs fromWT or knockout mice [17,44–46].
As mice deﬁcient for RARα or RARγ are viable, bone marrow cells
isolated from such mice provided interesting tools to study the role of
the individual receptors. Strategies for spatio-temporally controlled
somatic mutagenesis of RARs and for RAR overexpression were also
designed. These genetic studies were completed by the analysis of VAD
animals, and by pharmacological studies based on the use of selective
RAR agonist or antagonists. Overall, they provided solid evidence that
RARα and RARγ are dispensable for hematopoiesis but that each RAR
has speciﬁc and distinct modulatory roles (Fig. 2).
4.1. Stem cells maintenance: Critical role for RARγ
Hematopoiesis requires not only the continuous production of
mature blood cells fromHSCs but also the maintenance of the HSC pool
and RARγ has been found to be a critical regulator of this balance [46].
Indeed bone marrow cells from RARγ null mice only, and not from
RARα−/− mice, exhibited markedly reduced numbers of HSCs
associated with increased numbers of more mature progenitor cells.
The observation that primitive precursors overexpressing RARγ
exhibited a more undifferentiated phenotype corroborated the role of
RARγ in HSCs maintenance.
4.2. Lymphocytes (B and T) and macrophages: A role for RARγ in
inﬂammatory cytokine production
B and T lymphocytes are derived from the multipotent common
lymphoid progenitors (CLP, Fig. 2) and are involved in the immune
response. Subsequent to the observation that RARγ expression is up
regulated in developingT lymphocytes [17], one suggested that this RAR
subtypewould play a role in lymphocyte function. However the analysis
Fig. 1. A. Schematic representation (not to scale) of the different domains of RARs with the main phosphorylation sites. RARs consist mainly of an N-terminal domain (NTD), and a central
DNA-bindingdomain (DBD) linked toaC-terminal ligand-bindingdomain (LBD). The LBD iscomposedof12conservedαhelices andaβ-turn separatedbydisordered loops. Thestructures in
the absence (PDB1LBD) and in thepresence (PDB2LBD) of ligand are shownwith the swing of helix 12. The serine located in loop L9-10 of RARα is also shown aswell as the cyclinH binding
site, which encompasses loop L8-9. B. Recapitulation of the phosphorylation cascade induced by RA. In response to RA, p38MAPK (a) and the downstream protein kinase MSK1 (b) are
activated.MSK1phosphorylateshistones atH3S10(c) aswell asRARαat a serine residue located in the LBD(d). Subsequently, thecyclinH subunit of theCAKsubcomplexof TFIIH is recruited
to an adjacent domain (e), allowing the formation of a RARα/TFIIH complex and the phosphorylation of the NTD by the cdk7 kinase (f). Finally, RARα phosphorylated and associated with
TFIIH is recruited to response elements located in the promoter of target genes (g).
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hematopoietic cells indicated that RARγ is not essential for T and B
lymphocyte proliferation and differentiation [17]. RARγ was also
dispensable for antibody production by B cells. However, RARγ was
required for CD8+ T cell response and cytotoxicity, i.e., the production
of interferon gamma (IFN-γ), tumor necrosis factor alpha (TNFα) and
cytokines, which remove pathogens and induce inﬂammation. Most
interestingly, macrophages, which are derived from the multipotent
commonmyeloid progenitors (CMP) andwhich are also involved in theimmune response, also require RARγ for the production of inﬂamma-
tory cytokines [17,47]. It has been suggested that RARγwould regulate
the transcription of the cytokines genes by direct binding to promoter
regulatory elements. However the promoter regions of IL-6, IL-12, IFN-γ
and TNF-α do not contain any RARE, suggesting an indirect role of RARγ
that remains to be elucidated.
Paradoxically, RA and its derivatives suppress inﬂammation and
cytokine production in clinical treatments. Given that this effect was not
impaired in RARγ-deﬁcient macrophages and T cells [17], it has been
Fig. 2. Recapitulation of the different hematopoietic stages. The stages, which are regulated by RARs, are indicated. HSC, hematopoietic stem cells; CMP, commonmyeloid progenitor; CLP,
common lymphoid progenitor; MEP, megakaryocyte/erythroid progenitor; GMP, granulocyte/macrophage progenitor.
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the production of inﬂammatory cytokines such as the nuclear factor
kappa B (NFκB) pathway, which is critical for the expression of various
pro-inﬂammatory genes, including IL-6, IL-12, TNFα, and IFN-γ [48,49].
It has been proposed that the heterodimeric partner RXRα might bind
and inhibit NFκB [50]. However recent evidence rather suggests that RA
would suppress the expression of the inﬂammatory genes by inhibiting
kinasepathways independently of RARactivation [51–53].Whatever the
mechanism is, itmight be also at the basis of thebeneﬁcial effects of RA in
sustaining the stability and functionality of regulatory T cells (nTregs),
whichmaintain immunological homeostasis and self-tolerance and thus
play a crucial role in controlling autoimmune diseases [54].
4.3. Neutrophil differentiation: Bidirectional role of RARα
According to several studies, RA has the capacity to drive pluripotent
hematopoietic progenitors into the neutrophil lineage. RA can also
reprogram hematopoietic progenitors already engaged in another
lineage into the neutrophil fate, indicating that RA plays an important
role in controlling granulopoiesis. According to genetic and pharmaco-
logical studies, neutrophil differentiation is regulated essentially by
RARα, which plays a bidirectional role, inhibiting differentiation when
unliganded or bound to antagonists and promoting differentiation
when bound to RA or speciﬁc RARα agonists [44,45]. In line with this,
RARα antagonists promoted the accumulation of immature neutrophils
and overexpression of RARα inhibited neutrophil differentiation in the
absence of RA, but increased the sensitivity of the transduced cells to theantiproliferative and differentiative activity of RA and selective RARα
agonists. Moreover, progenitors from RARα−/− cells differentiated
faster into neutrophils, compared to cells from wild type mice [44].
Several RA target genes exempliﬁed by C/EBPε are activated during
the RA-induced differentiation of HSCs into neutrophils [40,44].
However, high throughput analysis should improve our understanding
of how RARα controls the expression of lineage-speciﬁc myeloid genes.
Nevertheless recent studies highlighted a novel level of regulation of
neutrophil differentiation by RARα via microRNAs. Indeed, speciﬁc
microRNAs are expressed in HSCs [55] and their expression is
dynamically regulated during early hematopoiesis and lineage com-
mitment [56]. Most interestingly, some of them are induced by RA [57]
and the promoters of the corresponding genes depict DR elements,
which bind RARα [58]. Further investigations should reveal how these
microRNAs orchestrate the transcription of speciﬁc genes and thereby
granulopoiesis.
Finally, given that MAPKs and other kinase signaling pathways play
critical roles in the maintenance of hematopoietic homeostasis [59,60],
one can suggest that RARα phosphorylation would also control
neutrophil differentiation. Results from our laboratory indicate that
indeed RARα is phosphorylated in myeloid cells (our unpublished
results). However in these cells, a loss of RARα phosphorylation by CAK
would be required for the expression of target genes and granulopoiesis
[61,62].
Of note is that cells of the neutrophil lineage express both the
RARα1 and RARα2 isoforms. It has been proposed that RARα2 would
be a more potent inhibitor of differentiation than RARα1 [44,63] but
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debated [64].
5. RARγ in skin proliferation and differentiation. Role in psoriasis?
In contrast to blood cells, the skin cells can renew but not fully
regenerate, making poorly satisfactory the prognosis of healing after
wound or deep burn. However, RA has long been known to inﬂuence
epidermal proliferation and to have a beneﬁt action during wound
healing. Indeed topical treatment of skin with retinoids induces
hyperproliferation of keratinocytes located in the basal layer, leading
to the thickening of the differentiated suprabasal layers and an
epidermal hyperplasia [15,65].
In human and mouse epidermis, RARγ represents 90% of the RARs
and thus is the predominant RAR, with the remaining 10% being RARα
andwith RARβbeingnot expressed [66]. The analysis ofmice selectively
lackingbothRARα andRARγ in adult epidermis by inducible conditional
somatic mutagenesis [15] demonstrated that the complete absence of
RARs in basal keratinocytes does not alter their homeostatic prolifer-
ation. Thus the self-renewal of epidermal keratinocytes does not seem
to require an epidermal RAR-dependent signaling pathway. However,
RARγ present in suprabasal keratinocytes was found to be involved in
the RA-induced hyperproliferation, which takes place in the basal layer,
through a paracrine signal. Therefore the beneﬁcial actions of retinoids
during wound healing have been attributed to this mechanism. It must
be noted that the injection of mesenchymal stem cells (MSCs) in skin
also has beneﬁts in skin repair and regeneration as they transdiffer-
entiate into keratinocytes [67]. However, the question whether RARγ
plays a role in this process still remains.
Retinoids are highly effective in the treatment of skin disorders such
as psoriasis and acne [68,69]. Psoriatic skin is characterized by
hyperproliferation of the basal epidermal layers and hyperkeratosis
but no clear-cut alterations in the expression levels and distribution of
RARshavebeen reported. In fact, psoriasis is essentially an inﬂammatory
disease in which skin contains large numbers of immune T cells and
macrophages that produce cytokines andother inﬂammatorymolecules
(interleukins, TNFα and IFN-γ) [70]. In line with this, the effects of
retinoids on this disease have been correlated to their ability to suppress
inﬂammation through inhibition of cytokineproduction (see above4.2).
Accordingly,microarray experiments indicated thatRAdownregulates a
great proportion of the psoriasis-related genes [71].
6. New unconventional roles for RARα in the nervous system
It has long been thought that the adultmammalian central nervous
system does not undergo notable cell turnover. However, recent
evidence has shown that neural stem cells are present in two
specialized niches of the adult brain, the subventricular zone and the
subgranular zone of the hippocampus. They maintain neurogenesis
and gliogenesis throughout adult life [72]. Several studies indicate
that RA induces the differentiation of these stem cells into neurons
[73,74], as described for multipotent embryonic stem cells [75–77].
However no genetic studies have been performed yet in the ﬁeld and
thus the question whether RARs are involved in neuronal stem cell
proliferation and differentiation still remains.
In fact, recent work highlighted an unexpected role for RARα in
neuron homeostatic plasticity. Indeed, the function of the normal
nervous system requires that, in the hippocampus, neurons maintain
a constant overall activity level that is achieved by homeostatic
synaptic plasticity [78]. This type of plasticity, manifested as increased
synaptic transmission in response to reduced neural activity, requires
the translation of new proteins such as the GluR1 receptors in
dendrites. Recently Aoto et al. [79] reported that RARα plays a role
during homeostatic plasticity by increasing the size of the postsyn-
aptic glutamate receptor response. RARα is expressed in the
hippocampus, but in addition to its classical presence in the nucleus,it is also present in neuronal dendrites [80]. During homeostatic
plasticity and in response to RA, RARα accumulates in dendrite
granules where it plays a non-genomic role as an mRNA binding
protein and stimulates GluR1 translation [81,82].
Finally, onemustnote that synapticplasticityunderlieshippocampus-
dependent spatial learning and memory [78]. Given that deﬁciencies in
retinoidmetabolism and signaling cause impaired synaptic plasticity and
learning [83], it has been suggested that such deﬁciencies might result in
neurological diseases [84]. One example is Alzheimer's disease, which is
associated with a variety of pathophysiological features including
amyloid plaque, inﬂammation, neurodegenerescence, altered neuro-
transmission and age-related changes [85]. In that context, retinoids are
candidate's drugs for treatment of this disease. [85,86]. This expands the
scope of the biological function of RARs and retinoids beyond their role as
regulators of gene transcription. Note however that RARα can also
regulate neurotransmission through the direct transcriptional regulation
of the dopamine D2 receptor [87].
7. RARs in cancers
In keeping with their ability to regulate growth and differentiation
throughout life, it is evident that abnormal expression and/or functions
of RARs might be involved in several cancers. Accordingly, RAR loss,
overexpression, mutations or aberrant post-traductional modiﬁcations
have been correlated with tumoral growth.
7.1. RARα rearrangements and mutations in myeloid leukemia (APL)
The blood system serves as a paradigm for understanding not only
stem cell biology and organogenesis but also oncogenesis. Indeed, in
humanmyeloid leukemia, the RARα gene is the target of chromosomal
rearrangements leading to the production of fusion proteins that allow
the cells to continue to proliferate and/or prevent the terminal
differentiation seen in normal myelocytes [88].
The best example is acute promyelocytic leukemia (APL or AML-M3
according to the FAB classiﬁcation) inwhichmaturation arrest occurs at
the level of thepromyelocyte (Fig. 2). InAPLs the rearrangements lead to
the production of fusion proteins containing a ﬁxed C-terminal portion
corresponding tomost of the RARα polypeptide (including theDBD and
the LBD) and a variable N-terminal portion originating from the PML,
PLZF, NuMA, nucleophosmin or STAT5b proteins (for review, see
reference [89]). Recently, novel rearrangements have been identiﬁed
involving the regulatory type I alpha subunit of PKA [90] and FIP1L1 [91].
A number of laboratories analyzed how these rearrangements disturb
the functions of normal RARα in controlling the proliferation of
promyelocytes and their differentiation into neutrophils.
Most of the studies have been performed on PML-RARα, which
results from the reciprocal translocation t (15; 17) [92] and which is
involved in N95% of cases. At themolecular level, PML-RARα behaves as
an altered RARwith stronger repressive activities. Indeed, in contrast to
RARα, PML-RARα has the ability to homodimerize or oligomerize with
or without union to RXRα [93,94]. Such a property expands the
recruitment of corepressor complexes encompassing a wide spectrum
of epigenetic enzymes with strong repressive properties towards target
genes [95]. Moreover, according to recent high throughput studies [21],
the oligomeric PML-RARα complexes also gain an expanded DNA-
binding capacity away from the classical DR5, DR2 and DR1 motifs
towards more widely spaced DRs. Finally, PML-RARαwas also found to
repress the expression of microRNA genes and thus to increase the
expression of key cancer proteins [58].
Another important property is that, in contrast to RARα, the
PML-RARα fusion protein is insensitive to physiological concentrations
of RA and requires higher pharmacological concentrations to overcome
the transcription and differentiation block [96]. Such pharmacological
doses of RA induce the release of microRNA expression [58], as well as
large-scale epigenetic changes (H3 acetylation, H3K27 methylation,
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interestingly, the global changes in repressive marks are not triggered
by the release of the chromatin-modifying enzymes from the PML-
RARα complex itself but by the rapid loss of the fusion protein at the
DNA-binding sites ([21] andCassinat et al.,manuscript submitted). Such
changes in the epigenetic landscape of APL cells have been correlated to
the reversal of the differentiation block and to the cessation of
proliferation and thus are at the basis of therapies combining RA and
epi-drugs such as HDACs [96–98].
It must be noted that some APL patients depict mutations in the
ligand-binding domain (LBD) of the RARα portion of the PML-RARα
fusion protein [99,100]. Some of these patients had point mutations in
the ligand-binding pocket that disrupted RA binding. Others had
mutations that produced extensive deletion of the entire LBD. All
thesemutations have been associatedwith poor clinical income, relapse
and RA resistance. However, signaling pathways such as G-CSF were
recently found to achieve the differentiation of such RA-resistant
leukemic cells [101]. Though themolecularmechanism of the release of
the RA resistance by G-CSF still remains ill deﬁned, recent studies
highlighteda key role forMAPK. Indeed,when combinedwithRA,G-CSF
restores the expression of RARα-target genes through the activation of
the MAPK/ERK pathway [102] and the subsequent relief of aberrant
epigenetic modiﬁcations of histones (Cassinat et al., manuscript
submitted).
Finally, it must be noted that, due to their quiescent state, several
leukemic stem cells resist to RA treatment, resulting in disease relapse.
Therefore new therapeutic approaches based on the proteasomal
degradation of the PML-RARα oncoprotein have been developed in
order to trigger the eradication of the leukemia-initiating cells and thus
long-term remission [103–105]. Such therapies combine RA to arsenic
and/or agents that activate cyclic AMP signaling [106,107].
7.2. Loss of RARβ and RARγ in cancers: Are RARs tumor suppressors?
In several tissues and organs, the loss of a RAR subtype has been
associatedwith tumorigenesis. Consequently, RARshavebeenconsidered
as tumor suppressors. In keratinocytes, it is the RARγ subtype that has
been considered as a tumor suppressor. Indeed, in KO mice, the loss of
RARγ predisposed skin to tumors [108] and RARγwas found to be absent
in oral keratinocytes from head and neck cancers [109]. In addition,
premature skin aging and skin cancer induced by UV radiation from the
sun have been correlated to a dramatic decrease in RARγ levels
subsequently to theUV-induced proteasomal degradation of the receptor
[110,111].
In contrast, inother tissues andorgans suchas lung, breast and cervix,
it is the loss of RARβ expression that has been associated with
tumorigenesis. Indeed, in such cancers, the RARβ gene is frequently
deletedor theRARβpromoter silenceddue to aberrantDNAmethylation
or repressive histone modiﬁcations [96,112–115]. Accordingly, reex-
pression of RARβ [116] or restoration of the RARβ promoter activity by
demethylation of DNA or HDAC inhibition [117,118] decreased the
tumorigenicity of the cancer cells.
The mechanism of the tumor suppressive effect of RARs is still
debated but according to several studies, RARs would block tumor
promotion through inhibiting the activity of the AP-1 complex
(heterodimers of the proto-oncogene products c-Fos and c-Jun),
which is known to regulate the expression of several genes involved
in oncogenesis and cell transformation and which is controlled by a
complex network of phosphorylations by stress-kinases ([1,96] and
references therein). Though several models have been proposed, the
molecular basis of the anti-AP-1 activity of RARs is still debated [1,96].
Nevertheless, AP-1 inhibition generally correlates with the growth
inhibitory effect of retinoids on tumors. Therefore, the capacity of RARs
to inhibit AP-1-responsive genes seems to be the basis for the
chemopreventive and chemotherapeutic effects of RA in the treatment
of hyperproliferative diseases [96].Note that in one leukemic patient, a RARα mutant named
RARα1delBC (deleted for the DBD and the N-terminal domain) has
been isolated [119]. However no speciﬁc correlationswith the growth of
the leukemic cells have been found yet.
7.3. Non-classic roles of RARs in tumor cells growth
Unexpectedly, in some cases, RARs have been correlated with
survival instead of growth arrest. As an example, in hepatocellular
carcinoma, RARγ has been found to be overexpressed [120] and to
contribute to cell growth through its altered subcellular localization and
strong cytoplasmic accumulation. Indeed, in the cytosol, RARγ interacts
with the p85α regulatory subunit of PI3K leading to the activation of the
PI3K/Akt pathway, which is one of the major survival pathways in
cancer cells [121]. Another example, still in the liver, is RARα, which
behaves as an oncogene in the absence of the corepressor TRIM24
(TIF1α) [122].
One must note that in breast cancer cells, RARα expression can be
inducedbyestrogens.MoreoverRARαhas been shownto sharewith the
estrogen receptor ERα, a subset of binding regions within the genome
[123,124] and to be part of the ER transcriptional complexes [124].
Through this mechanism, which is distinct from the classical one, it has
been proposed that RARα would participate to estrogen-mediated
proliferation. Note however that this model occurs only in the presence
of estrogens and is not incompatible with a shift towards the classical
antiproliferative activity of RARα upon RA addition.
Finally, in some cancers, RAdoes not inhibit cell growthbut promotes
cell survival. Unexpectedly, studies fromNoy's laboratory demonstrated
that this effect is not mediated by RARs but by the activation of the
orphan peroxisome proliferation-activated receptor β/δ (PPARβ/δ),
which in turn induces the expression of survival genes [125]. This shift
in RA signalingwould be regulated by the ratio between the CRABPII and
FABP5 proteins, which speciﬁcally deliver RA to RARs and PPARβ/δ
respectively.
7.4. Aberrant RAR phosphorylations
Today, new roles for phosphorylation in the regulation of RAR
functions are being discovered at an accelerated pace. Accordingly, it is
now increasingly clear that cancers are characterized by ampliﬁed or
deregulated cytosolic kinase cascades [126], ending at Akt or at different
MAPKs (Erks, JNKs, p38MAPK), which enter the nucleus. Breast cancers
characterized by the overexpression of the receptor tyrosine kinase
ErbB-2 [127–129] are a typical example of such cancers, which are
generally resistant to the antiproliferative action of RA [130]. In these
cancers (Duong et al., manuscript in preparation) and others [131,132],
RARα is aberrantly phosphorylated. Subsequently, RARα is degraded
and/or its transcriptional activity is abrogated.
Note that inxerodermapigmentosumpatients,whoare characterized
by mutations affecting subunits of the core of TFIIH, RARα is not
efﬁciently phosphorylated by the cdk7/cyclinH/MAT1 subcomplex of the
general transcription factor TFIIH. This deﬁcient phosphorylation has
characteristic downstreamconsequences on the expressionof RAR target
genes [133]. This has been correlated at least in part to the clinical
abnormalities of the patients but also to their high risk of skin cancer in
response to UV.
8. Conclusion and future directions
Analogous to theparadigmestablishedby thehematopoietic system,
there is now increasing evidence for the existence of stem cells and a
differentiation hierarchy in most adult tissues, including brain [72], the
mammary gland [134] and dermis [67]. In this review we have
highlighted that strictly controlled levels of RARs are necessary for the
correct balance between self-renewal and differentiation of tissue stem
cells (Table 1). Thus, the integrity of RARs is absolutely required for
Table 1
Recapitulation of RAR functions during homeostasis and of their deregulation in cancers
or diseases.
Tissue RAR Physiological
role
Associated
disease
RAR alterations
Bone
marrow
RARα Neutrophil
différentiation
[44,45]
Leukemia
(APL)
RARα chromosomal
translocations [88,89]
Mutations in RARα LBD
[99,100]
RARγ HSC renewal
[46]T cell CD8+
cytotoxicity
[17]
Inﬂammation
Fibroblasts RARα Growth control Xeroderma
pigmentosum
RARα
hypophosphorylation [133]
Liver RARγ/
RARα
Growth control Cancer RARγ overexpression/
cytosolic localization [120]
Loss of TRIM24 [122]
Lung RARβ/
RARα
Growth control Cancer RARβ deletion/silencing
[96,112,113]RARα aberrant
phosphorylation [131,132]
Mammary
gland
RARβ/
RARα
Growth control Cancer RARβ deletion/silencing
[115]RARα aberrant
phosphorylation [131,132]
Neurons RARα Plasticity [79] Alzheimer?
[85,86]
Skin RARγ Keratinocyte
proliferation
[15]
Aging/cancer RARγ loss [109–111]
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tion,mutations or aberrantmodiﬁcations of a speciﬁc RAR predispose to
cancer and lead to uncontrolled proliferation and/or to differentiation
block (Table 1). Therefore, deciphering how RARs and retinoids control
the expression of subsets of target genes is a continuous challenge in
homeostasis, oncogenesis and therapy. In line with this, microRNAs
appear to be novel and promising RARs targets, not only during
homeostatic cell fate determination but also in cancer therapy [55,58].
It is important to note that in addition to its ability to control cell
growth anddifferentiation, RAhas been recently shown to regulate lipid
homeostasis [135]. However this effect ismediated not only byRARs but
also by the peroxisome proliferation-activated receptor β/δ (PPARβ/δ),
introducing an additional level of complexity. Finally, it is getting
increasingly evident that RARs are involved in unconventional non-
genomic effects such as neuron plasticity [79], opening new avenues of
investigations.
Here we did not cover RXRs, the RAR partners, but it is evident that
they also play a role in homeostasis [16,136] and that their expression
levels [112,137] as well as their post-traductional modiﬁcations [138]
are affected in several diseases and cancers.
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